References
- McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, C V G, Kelly C, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA). Clin Infect Dis. [Internet] 2018 [cited 2018 Feb 22]; 31:431–10. Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/cix1085/4855916.
- Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore DJ, Colville A, Bhala N, Iqbal TH, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British society of gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. [Internet] 2018 [cited 2018 Sep 5]; 67:1920–1941. Available from: http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-316818.
- Allegretti JR, Mullish BH, Kelly C, Fischer M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet. [Internet] 2019 [cited 2019 Aug 5]; 394:420–431. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31266-8/fulltext#.
- DeFilipp Z, Bloom PP, Soto MT, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen Bin Y, Hohmann EL. Drug-resistant e. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. [Internet] 2019 [cited 2019 Nov 16]; 381:2043–2050. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31665575.
- Duvallet C, Zellmer C, Panchal P, Budree S, Osman M, Alm EJ. Framework for rational donor selection in fecal microbiota transplant clinical trials. PLoS One. [Internet] 2019 [cited 2020 Apr 29]; 14:e0222881. Available from: http://dx.plos.org/10.1371/journal.pone.0222881.
- Smillie CS, Sauk J, Gevers D, Friedman J, Sung J, Youngster I, Hohmann EL, Staley C, Khoruts A, Sadowsky MJ, et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe. [Internet] 2018 [cited 2019 Feb 27]; 23:229–240.e5. Available from: https://www.sciencedirect.com/science/article/pii/S1931312818300386?via%3Dihub.
- Staley C, Kaiser T, Vaugh BP, Graiziger CT, Hamilton MJ, Khoruts A, Sadowsky MJ, Vaughn BP, Graiziger CT, Hamilton MJ, et al. Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. Microbiome. [Internet] 2018 [cited 2018 Oct 6]; submitted:166. Available from]. []:. https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0549-6.
- Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K, Allen-Vercoe E. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: “RePOOPulating” the gut. Microbiome. [Internet] 2013 [cited 2017 Oct 3]; 1:3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24467987.
- Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, Lombardo M-J, Vulic M, Ohsumi T, Winkler J, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. [Internet] 2016 [cited 2017 Oct 3]; 214:173–181. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26908752.
- Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, Cassidy L, Tholey A, Fickenscher H, Seegert D, et al. Efficacy of sterile fecal filtrate transfer for treating patients with clostridium difficile infection. Gastroenterology. [Internet] 2017 [cited 2017 Jun 9]; 152:799–811.e7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0016508516353549.
- Zuo T, Wong SH, Cheung CP, Lam K, Lui R, Cheung K, Zhang F, Tang W, Ching JYL, Wu JCY, et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat Commun. [Internet] 2018 [cited 2019 Feb 22]; 9:3663. Available from: http://www.nature.com/articles/s41467-018-06103-6.
- Draper LA, Ryan FJ, Smith MK, Jalanka J, Mattila E, Arkkila PA, Ross RP, Satokari R, Hill C. Long-term colonisation with donor bacteriophages following successful faecal microbial transplantation. Microbiome. [Internet] 2018 [cited 2018 Dec 21]; 6:220. Available from: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0598-x.
- Zuo T, Wong SH, Lam K, Lui R, Cheung K, Tang W, Ching JYL, Chan PKS, Chan MCW, Wu JCY, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut. [Internet] 2017 [cited 2017 Oct 7];: gutjnl-2017-313952. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28539351.
- Park H, Laffin MR, Jovel J, Millan B, Hyun JE, Hotte N, Kao D, Madsen KL. The success of fecal microbial transplantation in Clostridium difficile infection correlates with bacteriophage relative abundance in the donor: a retrospective cohort study. Gut Microbes. [Internet] 2019 [cited 2020 May 12]; 10:676–687. Available from: https://www.tandfonline.com/doi/full/10.1080/19490976.2019.1586037.
- Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for clostridium difficile spores. J Bacteriol. [Internet] 2008 [cited 2017 Oct 7]; 190:2505–2512. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18245298.
- Sorg JA, Sonenshein AL. Inhibiting the initiation of clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol. [Internet] 2010 [cited 2018 Jan 16]; 192:4983–4990. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20675492.
- Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, Huffnagle GB, Li ZJ, Young VB, Bowman AA, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. [Internet] 2014 [cited 2017 Oct 7]; 5:3114. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863611/pdf/sph0046.pdf.
- Jones BV, Begley M, Hill C, Gahan CGM, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A. [Internet] 2008 [cited 2017 Oct 7]; 105:13580–13585. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18757757.
- Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. [Internet] 2006 [cited 2017 Oct 7]; 47:241–259. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16299351.
- Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. [Internet] 2014 [cited 2017 Oct 7]; 517:205–208. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25337874.
- Studer N, Desharnais L, Beutler M, Brugiroux S, Terrazos MA, Menin L, Schürch CM, McCoy KD, Kuehne SA, Minton NP, et al. Functional intestinal bile acid 7α-dehydroxylation by clostridium scindens associated with protection from clostridium difficile infection in a gnotobiotic mouse model. Front Cell Infect Microbiol. [Internet] 2016 [cited 2018 May 2]; 6:191. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28066726.
- Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Liver Physiol. 2014;306:G310–9.
- Mullish BH, McDonald JAKK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGMM, et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut. [Internet] 2019 [cited 2019 Feb 11]; 68:1791–1800. Available from: https://gut.bmj.com/content/early/2019/02/11/gutjnl-2018-317842.
- Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JR. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. [Internet] 2016 [cited 2017 Oct 7]; 43:1142–1153. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27086647.
- Seekatz AM, Theriot CM, Rao K, Chang Y-M, Freeman AE, Kao JY, Young VB. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe. [Internet] 2018 [cited 2019 Mar 4]; 53:64–73. Available from: https://www.sciencedirect.com/science/article/pii/S1075996418300581#bib52.
- Kang JD, Myers CJ, Harris SC, Kakiyama G, Lee I-K, Yun B-S, Matsuzaki K, Furukawa M, Min H-K, Bajaj JS, et al. Bile acid 7α-dehydroxylating gut bacteria secrete antibiotics that inhibit clostridium difficile: role of secondary bile acids. Cell Chem Biol. [Internet] 2019 [cited 2019 Mar 9]; 26:27–34.e4. Available from: https://www.sciencedirect.com/science/article/pii/S2451945618303350.
- Monaghan T, Mullish BH, Patterson J, Wong GKSK, Marchesi JR, Xu H, Jilani T, Kao D. Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway. Gut Microbes. [Internet] 2019 [cited 2018 Sep 9]; 10:1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30183484.
- Winston JA, Rivera AJ, Cai J, Thanissery R, Montgomery SA, Patterson AD, Theriot CM. Ursodeoxycholic acid (udca) mitigates the host inflammatory response during clostridioides difficile infection by altering gut bile acids. Infect Immun. [Internet] 2020 [cited 2020 Jul 8]; 88. Available from: https://pubmed.ncbi.nlm.nih.gov/32205405/.
- Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S, Klomp LWJ, Siersema PD, Schipper MEI, Danese S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. [Internet] 2011 [cited 2019 Mar 7]; 60:463–472. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21242261.
- Campbell C, McKenney PT, Konstantinovsky D, Isaeva OI, Schizas M, Verter J, Mai C, Jin W-B, Guo C-J, Violante S, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nat. 2020;2020:1–5.
- Cook S. Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther. [Internet] 1998 [cited 2019 Feb 24]; 12:499–507. doi:10.1046/j.1365-2036.1998.00337.x.
- McDonald JAK, Mullish BH, Pechlivanis A, Liu Z, Brignardello J, Kao D, Holmes E, Li JV, Clarke TB, Thursz MR, et al. Inhibiting growth of clostridioides difficile by restoring valerate, produced by the intestinal microbiota. Gastroenterology. [Internet] 2018; 155:1495–1507.e15. doi:10.1053/j.gastro.2018.07.014.
- Fachi JL, De Felipe JS, Pral LP, Da Silva BK, Corrêa RO, De Andrade MCP, Da Fonseca DM, Basso PJ, Câmara NOS, De Sales E Souza ÉL, et al. Butyrate protects mice from clostridium difficile-induced colitis through an HIF-1-dependent mechanism. Cell Rep. [Internet] 2019 [cited 2020 Jul 8]; 27:750–761.e7. Available from: https://pubmed.ncbi.nlm.nih.gov/30995474/.
- Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Tregcell homeostasis. Sci (80-). [Internet] 2013 [cited 2019 Mar 6]; 341:569–573. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23828891.
- Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. [Internet] 2014 [cited 2019 Mar 7]; 121:91–119. Available from: https://www.sciencedirect.com/science/article/pii/B9780128001004000039?via%3Dihub.
- Yuille S, Reichardt N, Panda S, Dunbar H, Mulder IE. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS One. [Internet] 2018 [cited 2019 Mar 7]; 13:e0201073. Available from: https://dx.plos.org/10.1371/journal.pone.0201073.
- Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, Mascagni P, Fantuzzi G, Dinarello CA, Siegmund B. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol. [Internet] 2006 [cited 2019 Mar 14]; 176:5015–5022. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16585598.
- Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, Chang HJ, Coward S, Goodman KJ, Xu H, et al. Effect of oral capsule– vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: A randomized clinical trial. JAMA - J Am Med Assoc. [Internet] 2017 [cited 2017 Dec 12]; 318:1985–1993. doi:10.1001/jama.2017.17077.
- Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: A platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002;1:153–161. doi:10.1038/nrd728.
- Bates D, Mächler M, Bolker BM, Walker SC. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1–48. doi:10.18637/jss.v067.i01.
- Cloarec O, Dumas ME, Craig A, Barton RH, Trygg J, Hudson J, Blancher C, Gauguier D, Lindon JC, Holmes E, et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem. 2005;77:1282–1289. doi:10.1021/ac048630x.
- Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in1H NMR metabonomics. Anal Chem. 2006;78:4281–4290. doi:10.1021/ac051632c.
- Yap IKS, Li JV, Saric J, Martin FP, Davies H, Wang Y, Wilson ID, Nicholson JK, Utzinger J, Marchesi JR, et al. Metabonomic and microbiological analysis of the dynamic effect of vancomycin-lnduced gut microbiota modification in the mouse. J Proteome Res. 2008;7:3718–3728. doi:10.1021/pr700864x.
- Zheng H, Yde CC, Clausen MR, Kristensen M, Lorenzen J, Astrup A, Bertram HC. Metabolomics investigation to shed light on cheese as a possible piece in the French paradox puzzle. J Agric Food Chem. 2015;63:2830–2839. doi:10.1021/jf505878a.
- Luo L, Hu M, Li Y, Chen Y, Zhang S, Chen J, Wang Y, Lu B, Xie Z, Liao Q. Association between metabolic profile and microbiomic changes in rats with functional dyspepsia. RSC Adv. 2018;8:20166–20181. doi:10.1039/C8RA01432A.
- Koeth RA, Lam-Galvez BR, Kirsop J, Wang Z, Levison BS, Gu X, Copeland MF, Bartlett D, Cody DB, Dai HJ, et al. L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest. 2019;129(1):373–387.
- Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576–585. doi:10.1038/nm.3145.
- Smits LP, Kootte RS, Levin E, Prodan A, Fuentes S, Zoetendal EG, Wang Z, Levison BS, Cleophas MCP, Kemper EM, et al. Effect of vegan fecal microbiota transplantation on carnitine‐ and choline‐derived trimethylamine‐N‐oxide production and vascular inflammation in patients with metabolic syndrome. J Am Heart Assoc. [Internet] 2018 [cited 2020 May 7]; 7. Available from: https://www.ahajournals.org/doi/10.1161/JAHA.117.008342.
- Wu WK, Chen CC, Liu PY, Panyod S, Liao BY, Chen PC, Kao HL, Kuo HC, Kuo CH, Chiu THT, et al. Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice. Gut. 2019;68:1439–1449. doi:10.1136/gutjnl-2018-317155.
- Passmore IJ, Letertre MPM, Preston MD, Bianconi I, Harrison MA, Nasher F, Kaur H, Hong HA, Baines SD, Cutting SM, et al. Para-cresol production by Clostridium difficile affects microbial diversity and membrane integrity of Gram-negative bacteria. PLoS Pathog. 2018;14(9):e1007191.
- Diether N, Willing B. Microbial fermentation of dietary protein: an important factor in diet–microbe–host interaction. Microorganisms. [Internet] 2019 [cited 2020 May 4]; 7:19. Available from: http://www.mdpi.com/2076-2607/7/1/19.
- Persico AM, Napolioni V. Urinary p-cresol in autism spectrum disorder. Neurotoxicol Teratol. 2013;36:82–90. doi:10.1016/j.ntt.2012.09.002.
- Saito Y, Sato T, Nomoto K, Tsuji H. Identification of phenol- and p-cresol-producing intestinal bacteria by using media supplemented with tyrosine and its metabolites. FEMS Microbiol Ecol. [Internet] 2018 [cited 2020 Jul 8]; 94. Available from: https://pubmed.ncbi.nlm.nih.gov/29982420/.